Aromatase inhibitors and mood disturbances

Palliative and Supportive Care

Volumn 10, Issue 3, 2012, Pages 225-227

  Rocha Cadman, Xiomara ^a   Massie, Mary Jane ^a   Du Hamel, Katherine ^a  

^a Memorial Hospital for Cancer and Allied Diseases   (United States)

Author keywords

Aromatase inhibitors; breast cancer; estrogen; mood; tamoxifen

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST TUMOR; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; MIDDLE AGED; MOOD DISORDER;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; MOOD DISORDERS; TAMOXIFEN;

EID: 84865712506     PISSN: 14789515     EISSN: 14789523     Source Type: Journal    
DOI: 10.1017/S1478951512000636     Document Type: Article

References (11)

1. Berry, J. (2005). Are all aromatase inhibitors the same? A reviewof controlled clinical trials in breast cancer. Clinical Therapeutics Journal, 27, 1671-1684. (Pubitemid 41815221)
2. Campos, S. (2003). Aromatase inhibitors for breast cancer in postmenopausal women. The Oncologist, 9, 126-136.
3. Fink, G., Sumner, B.E., Rosie, R., Grace, O. & Quinn, J.P. (1996). Estrogen control of central neurotransmission: Effect on mood, mental state and memory. Cellular and Molecular Neurobiology, 16, 325-344. (Pubitemid 26231262)
4. Fontaine, C., Meulemasns, A., Huizing, M., et al. (2008). Tolerance of adjuvant letrozole outside of clinical trials. The Breast, 17, 376-381.
5. Goodwin, G. (2006). Aromatase inhibitors and bipolar mood disorder: A case report. Bipolar Disorder, 8, 516-518. (Pubitemid 44560227)
6. Henry, N.L., Stearns, V., Flockhart, D.A., et al. (2008). Drug interactions and pharmacogenomics in the treatment for breast cancer and depression. American Journal of Psychiatry, 165, 1251-1255.
7. Lake, D.&Hudis, C. (2003). Aromatase inhibitors in breast cancer: An update cancer control. Journal of the Moffitt Cancer Center
8. Howell, A., Cuzick, J., Baum, M., et al. (2005). Results of the ATAC (Arimidex, tamoxifen, Alone, or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. The Lancet, 365, 60-62.
9. Perez, E.A. (2007). Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormoneresponsive early breast cancer. Annals Oncology, 18, viii-viii 35.
10. Thomas, R., Williams, M., Marshall, C., et al. (2008). Switching to letrozole or exemestane improves hot flushes, mood and quality if life in Tamoxifen intolerant women. British Journal of Cancer, 98, 1494-1499. (Pubitemid 351652326)
11. Tomao, F., Spinelli, G., Vici, P., et al. (2011). Current role and safety profile of aromatase inhibitors in early breast. Cancer Expert Rev Anticancer Therapy, 11, 1253-1263.